表紙
市場調査レポート

世界の過敏性腸症候群(IBS)市場の将来動向

Global Irritable Bowel Syndrome Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 319668
出版日 ページ情報 英文 86 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
世界の過敏性腸症候群(IBS)市場の将来動向 Global Irritable Bowel Syndrome Market 2015-2019
出版日: 2014年11月19日 ページ情報: 英文 86 Pages
概要

過敏性腸症候群(IBS)は消化器系に一般的に見られる疾患で、腹部痙攣や不快感、膨満感、便秘、下痢などの症状を引き起こします。炎症性腸疾患(再発性免疫反応や消化管の炎症を伴う慢性疾患)は往々にして、IBSと誤診されることがあります。IBSの症状は、一般的に30歳前後の患者に多く見られます。CDCによれば、IBSの一般的な症状には、極度の膨満感や重い胃痙攣・腹痛、腰痛、鼠径部痛、胸焼け、胃酸過多、脚部のうずくような痛み、食後の立ちくらみなどがあります。世界の過敏性腸症候群市場の2014〜2019年の年平均成長率(CAGR)は14.04%に達する、と予測されています。

当レポートでは、全世界の過敏性腸症候群(IBS)治療薬の市場について分析し、市場の概要や構造、市場規模の動向(今後5年間の予測値)、地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・考察しております。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 製品プロファイル

  • Linzess
  • Irribow/Irribow OD
  • Lotronex
  • Amitiza

第5章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第6章 イントロダクション

第7章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第8章 作用機序による市場区分

  • グアニル酸シクラーゼ受容体C作動薬
  • 5HT3受容体拮抗薬
  • 塩素チャネル活性化剤
  • その他

第9章 市場区分:剤形別

  • 固形剤
  • 液剤

第10章 適応症による市場区分

  • IBS-C
  • IBS-D

第11章 エンドユーザーの性別による市場区分

  • 女性
  • 男女両方

第12章 地理区分

第13章 罹患率と有病率

第14章 購入基準

第15章 市場成長因子

第16章 成長因子とその影響

第17章 市場の課題

第18章 成長因子と課題の影響

第19章 市場動向

第20章 動向とその影響

第21章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • 企業合併・買収(M&A)
  • 市場シェア分析2014
    • 武田薬品工業
    • Nestle
    • Actavis
    • アステラス製薬
  • その他および将来の有力ベンダー

第22章 パイプラインポートフォリオ

第23章 主要ベンダーの分析

  • Actavis
    • 主要データ
    • 事業内容
    • 事業区分
    • 部門別の市場収益額2012および2013
    • 地域別の売上高
    • 事業戦略
    • 主要情報
    • SWOT分析
  • アステラス製薬
  • Nestle
  • 武田薬品工業

第24章 関連レポート

図表一覧

目次
Product Code: IRTNTR4709

About Irritable Bowel Syndrome

Irritable bowel syndrome is a common disorder of the digestive system causing abdominal cramps, discomfort, bloating, constipation, and diarrhea. Inflammatory bowel disease, which is a chronic disease with recurrent immune response and inflammation of the GI tract, is sometimes confused with irritable bowel syndrome. The symptoms of irritable bowel syndrome generally appear in a patient aged around 30 years. According to the CDC, prominent symptoms of irritable bowel syndrome include severe bloating, severe stomach cramps or abdominal pain, lower back pain, groin pain, heartburn, acidity, shooting pain in the legs, and lightheadedness after eating.

TechNavio's analysts forecast the Global Irritable Bowel Syndrome market to grow at a CAGR of 14.04 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Irritable Bowel Syndrome market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of irritable bowel syndrome.

TechNavio's report, Global Irritable Bowel Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Irritable Bowel Syndrome market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Actavis
  • Astellas Pharma
  • Nestle
  • Takeda Pharmaceutical

Other Prominent Vendors

  • Abbott
  • Alba Therapeutics
  • Alfa Wassermann
  • Alizyme
  • Almirall
  • AltheRx Pharmaceuticals
  • Ardelyx
  • AstraZeneca
  • Bayer
  • Bristol Myers Squibb
  • Dainippon Sumitomo Pharma
  • Dong-A Socio Holdings
  • Drais Pharmaceuticals
  • Dynogen
  • gIcare Pharma
  • GlaxoSmithKline
  • Hanmi Pharmaceuticals
  • ImmusanT
  • Ironwood
  • Janssen
  • Lexicon Pharmaceuticals
  • Menarini
  • MicroDose Therapeutx
  • Norgine
  • Novartis
  • Ocera Therapeutics
  • Ono Pharmaceutical
  • Par Pharmaceutical
  • Pfizer
  • Pharmos
  • Protagonist Therapeutics
  • RaQualia Pharma
  • Rottapharm
  • Salix
  • Seldar Pharma
  • Shire
  • SK Chemicals
  • SOFAR
  • Synergy Pharmaceuticals
  • Synthetic Biologics
  • Tioga Pharmaceuticals
  • Tsumura
  • Yuhan

Market Driver

  • Presence of Unmet Need
  • For a full, detailed list, view our report

Market Challenge

  • High Cost of Therapy
  • For a full, detailed list, view our report

Market Trend

  • Rise in Public Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Linzess
    • 04.1.2. Irribow/Irribow OD
    • 04.1.3. Lotronex
    • 04.1.4. Amitiza

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Mechanism of Action

  • 08.1. Guanylate Cyclase Receptor-C Agonist
  • 08.2. 5HT3 Antagonist
  • 08.3. Chloride Channel Activator
  • 08.4. Others

09. Market Segmentation by Dosage Form

  • 09.1. Solid
  • 09.2. Liquid

10. Market Segmentation by Indication

  • 10.1. IBS-C
  • 10.2. IBS-D

11. Market Segmentation by End User Gender

  • 11.1. Female
  • 11.2. Both

12. Geographical Segmentation

13. Rate of Incidence and Prevalence

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2014
    • 21.2.1. Takeda
    • 21.2.2. Nestle
    • 21.2.3. Actavis
    • 21.2.4. Astellas
  • 21.3. Other and Future Prominent Vendors

22. Pipeline Portfolio

23. Key Vendor Analysis

  • 23.1. Actavis
    • 23.1.1. Key Facts
    • 23.1.2. Business Description
    • 23.1.3. Business Segmentation
    • 23.1.4. Business Segmentation by Revenue 2012 and 2013
    • 23.1.5. Sales by Geography
    • 23.1.6. Business Strategy
    • 23.1.7. Key Information
    • 23.1.8. SWOT Analysis
  • 23.2. Astellas Pharma
    • 23.2.1. Key Facts
    • 23.2.2. Business Overview
    • 23.2.3. Product Segmentation
    • 23.2.4. Product Segmentation by Revenue 2012 and 2013
    • 23.2.5. Geographical Segmentation by Revenue 2013
    • 23.2.6. Business Strategy
    • 23.2.7. Recent Developments
    • 23.2.8. SWOT Analysis
  • 23.3. Nestle
    • 23.3.1. Key Facts
    • 23.3.2. Business Overview
    • 23.3.3. Business Segmentation by Revenue 2013
    • 23.3.4. Business Segmentation by Revenue 2012 and 2013
    • 23.3.5. Geographical Segmentation by Revenue 2013
    • 23.3.6. Business Strategy
    • 23.3.7. Recent Developments
    • 23.3.8. SWOT Analysis
  • 23.4. Takeda Pharmaceuticals
    • 23.4.1. Key Facts
    • 23.4.2. Business Overview
    • 23.4.3. Business Segmentation by Revenue 2013
    • 23.4.4. Business Segmentation by Revenue 2013
    • 23.4.5. Geographical Segmentation by Revenue 2013
    • 23.4.6. Business Strategy
    • 23.4.7. Recent Developments
    • 23.4.8. SWOT Analysis

24. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Irritable Bowel Syndrome Market 2014-2019 (US$ million)
  • Exhibit 3: Global Irritable Bowel Syndrome Market Segmentation by Mechanism of Action
  • Exhibit 4: Global Irritable Bowel Syndrome Market Segmentation by Mechanism of Action 2014
  • Exhibit 5: Global Irritable Bowel Syndrome Market Segmentation by Dosage Form
  • Exhibit 6: Global Irritable Bowel Syndrome Market Segmentation by Dosage Form 2014
  • Exhibit 7: Global Irritable Bowel Syndrome Market Segmentation by Indication
  • Exhibit 8: Global Irritable Bowel Syndrome Market Segmentation by Mechanism of Action 2014
  • Exhibit 9: Global Irritable Bowel Syndrome Market Segmentation by End User Gender
  • Exhibit 10: Global Irritable Bowel Syndrome Market Segmentation by End User Gender 2014
  • Exhibit 11: Global Irritable Bowel Syndrome Market by Geographical Segmentation 2014
  • Exhibit 12: Prevalence of Irritable Bowel Syndrome in Japanese Females, by Type
  • Exhibit 13: Prevalence of Irritable Bowel Syndrome in Japanese Males, by Type
  • Exhibit 14: Global Irritable Bowel Syndrome Market Share Analysis 2014
  • Exhibit 15: Pipeline Portfolio of the Drug Candidates for Irritable Bowel Syndrome
  • Exhibit 16: Clinical Trials of Irritable Bowel Syndrome Drugs by Geography
  • Exhibit 17: Clinical Trials of Irritable Bowel Syndrome Drugs by Geography
  • Exhibit 18: Percentage of Clinical Trial Molecules in Each Phase
  • Exhibit 19: Actavis: Business Segmentation 2013
  • Exhibit 20: Actavis: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 21: Actavis : Sales by Geography (in US$ million)
  • Exhibit 22: Astellas Pharma: Product Segmentation 2013
  • Exhibit 23: Astellas Pharma : Product Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 24: Astellas Pharma: Geographical Segmentation by Revenue 2013
  • Exhibit 25: Nestle: Business Segmentation by Revenue 2013
  • Exhibit 26: Nestle: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 27: Nestle: Geographical Segmentation by Revenue 2013
  • Exhibit 28: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013
  • Exhibit 29: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013 (US$ million)
  • Exhibit 30: Takeda Pharmaceuticals: Geographical Segmentation by Revenue 2013
Back to Top